Advertisement

Meyka AI - Contribute to AI-powered stock and crypto research platform
Meyka Stock Market API - Real-time financial data and AI insights for developers
Advertise on Meyka - Reach investors and traders across 10 global markets
Loading...

Biome Australia Limited

BIO.AXASX
Healthcare
Biotechnology
$0.36
$-0.03(-6.41%)
Australian Market opens in 5h 46m

Biome Australia Limited Fundamental Analysis

Biome Australia Limited (BIO.AX) shows moderate financial fundamentals with a PE ratio of 88.79, profit margin of 4.36%, and ROE of 17.85%. The company generates $0.0B in annual revenue with strong year-over-year growth of 79.79%.

Key Strengths

PEG Ratio0.24
Current Ratio2.00

Areas of Concern

Operating Margin3.33%
Cash Position3.95%
We analyze BIO.AX's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 67.1/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.

Fundamental Health Score

C+
67.1/100

We analyze BIO.AX's fundamental strength across five key dimensions:

Efficiency Score

Weak

BIO.AX struggles to generate sufficient returns from assets.

ROA > 10%
7.78%

Valuation Score

Moderate

BIO.AX shows balanced valuation metrics.

PE < 25
88.79
PEG Ratio < 2
0.24

Growth Score

Excellent

BIO.AX delivers strong and consistent growth momentum.

Revenue Growth > 5%
79.79%
EPS Growth > 10%
47.71%

Financial Health Score

Excellent

BIO.AX maintains a strong and stable balance sheet.

Debt/Equity < 1
0.40
Current Ratio > 1
2.00

Profitability Score

Moderate

BIO.AX maintains healthy but balanced margins.

ROE > 15%
17.85%
Net Margin ≥ 15%
4.36%
Positive Free Cash Flow
Yes

Key Financial Metrics

Is BIO.AX Expensive or Cheap?

P/E Ratio

BIO.AX trades at 88.79 times earnings. This suggests a premium valuation.

88.79

PEG Ratio

When adjusting for growth, BIO.AX's PEG of 0.24 indicates potential undervaluation.

0.24

Price to Book

The market values Biome Australia Limited at 14.04 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

14.04

EV/EBITDA

Enterprise value stands at 113.22 times EBITDA. This signals the market has high growth expectations.

113.22

How Well Does BIO.AX Make Money?

Net Profit Margin

For every $100 in sales, Biome Australia Limited keeps $4.36 as profit after all expenses.

4.36%

Operating Margin

Core operations generate 3.33 in profit for every $100 in revenue, before interest and taxes.

3.33%

ROE

Management delivers $17.85 in profit for every $100 of shareholder equity.

17.85%

ROA

Biome Australia Limited generates $7.78 in profit for every $100 in assets, demonstrating efficient asset deployment.

7.78%

Following the Money - Real Cash Generation

Operating Cash Flow

Biome Australia Limited generates limited operating cash flow of $393.82K, signaling weaker underlying cash strength.

$393.82K

Free Cash Flow

Biome Australia Limited generates weak or negative free cash flow of $358.45K, restricting financial flexibility.

$358.45K

FCF Per Share

Each share generates $0.00 in free cash annually.

$0.00

FCF Yield

BIO.AX converts 0.42% of its market value into free cash.

0.42%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

88.79

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.24

vs 25 benchmark

P/B Ratio

Price to book value ratio

14.04

vs 25 benchmark

P/S Ratio

Price to sales ratio

3.90

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.40

vs 25 benchmark

Current Ratio

Current assets to current liabilities

2.001

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.18

vs 25 benchmark

ROA

Return on assets percentage

0.08

vs 25 benchmark

ROCE

Return on capital employed

0.11

vs 25 benchmark

How BIO.AX Stacks Against Its Sector Peers

MetricBIO.AX ValueSector AveragePerformance
P/E Ratio88.7928.25 Worse (Expensive)
ROE17.85%780.00% Weak
Net Margin4.36%-20122.00% (disorted) Weak
Debt/Equity0.400.30 Weak (High Leverage)
Current Ratio2.004.66 Strong Liquidity
ROA7.78%-14687.00% (disorted) Weak

BIO.AX outperforms its industry in 1 out of 6 key metrics, but lagging in P/E Ratio.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Biome Australia Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

3133.45%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

20.23%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

92.62%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ